Renwick AB, Watts PS, Edwards RJ, Barton PT, Guyonnet I, Price RJ, Tredger JM,
Pelkonen O, Boobis AR, Lake BG. Differential maintenance of cytochrome P450
enzymes in cultured precision-cut human liver slices. Drug Metab Dispos
2000;28:1202–1209.
Riley RJ, Howbrook D.In vitroanalysis of the activity of the major human hepatic CYP
enzyme (CYP3A4) using [N-methyl-^14 C]-erythromycin. J Pharmacol Toxicol
Methods 1997;38:189–193.
Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all
cyclooxygenase inhibitors the same? DrugMetab Dispos 2005;33:1567–575.
Sakai-Kato K, Kato M, Homma H, Toyo’oka T, Utsunomiya-Tate N. Creation
of a P450 array toward high-throughput analysis. Anal Chem 2005;77:7080–7083.
Segel IH. Citation-classic - enzyme-kinetics - behavior and analysis of rapid equilibrium
and steady-state enzyme-systems. Curr Contents/Life Sci 1987;14.
Shou M. Prediction of pharmacokinetics and drug–drug interactions fromin vitro
metabolism data. Curr Opin Drug Discov Devel 2005;8:66–77.
Shou M, Lin Y, Lu P, Tang C, Mei Q, Cui D, Tang W, Ngui JS, Lin CC, Singh R,
Wong BK, Yergey JA, Lin JH, Pearson PG, Baillie TA, Rodrigues AD, Rushmore
TH. Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab
2001;2:17–36.
Silverman RB. Mechanism-based enzyme inactivators. Methods Enzymol 1995;249:
240–283.
Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. Cytochrome P450
fluorometric substrates: identification of isoform-selective probes for rat CYP2D2
and human CYP3A4. Drug Metab Dispos 2002;30:845–852.
Thummel KE, Wilkinson GR.In vitroandin vivodrug interactions involving human
CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389–430.
Trubetskoy OV, Gibson JR, Marks BD. Highly miniaturized formats forin vitrodrug
metabolism assays using vivid fluorescent substrates and recombinant human
cytochrome P450 enzymes. J Biomol Screen 2005;10:56–66.
Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Human drug metabolism and the
cytochromes P450: application and relevance ofin vitromodels. J Clin Pharmacol
2001;41:1149–1179.
Von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI.In
vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol
1998;55:113–122.
Waley SG. Kinetics of suicide substrates. Biochem J 1980;185:771–773.
Walsh C, Cromartie T, Marcotte P, Spencer R. Suicide substrates for flavoprotein
enzymes. Methods Enzymol 1978;53:437–448.
Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug
Metab Dispos 2004;32:647–660.
Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY. Human cytochrome P-450 3A4:in
vitrodrug–drug interaction patterns are substrate-dependent. Drug Metab Dispos
2000;28:360–366.
Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil
enantiomers and their metabolites. Drug Metab Dispos 2004;32:259–266.
REFERENCES 543